Gilead Sciences Share Price (NASDAQ: GILD)

$118.35

▲

-0.67

(-0.56%)

Last updated on August 16, 2025 at 1:29 AM IST

$₹

Check the interactive Gilead Sciences Stock chart to analyse performance

Gilead Sciences stock performance

as on August 16, 2025 at 1:29 AM IST

Today's Low:$117.75
Today's High:$118.98
$118.35
0.51%
Downside
Day's Volatility :1.03%
Upside
0.53%
52 Weeks Low:$72.89
52 Weeks High:$121.83
$118.35
38.42%
Downside
52 Weeks Volatility :40.17%
Upside
2.86%

Gilead Sciences Stock Returns

Period	Gilead Sciences Inc.	Sector (Health Care)	Index (NASDAQ Composite)
3 Months	11.47%	2.3%	12.6%
6 Months	12.44%	-5.9%	8.0%
1 Year	58.95%	-10.9%	22.6%
3 Years	81.56%	2.3%	67.1%

Gilead Sciences Inc. Key Stats

Check Gilead Sciences key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$119.02
Open	$118.64
Today's High	$118.98
Today's Low	$117.75
Market Capitalization	$147.7B
Today's Volume	$8.9M
52 Week High	$121.83
52 Week Low	$72.885
Revenue TTM	$28.9B
EBITDA	$13.8B
Earnings Per Share (EPS)	$5.03
PE Ratio	23.66
Dividend Yield	2.6%
Profit Margin	21.87%
Quarterly Earnings Growth YOY	0.21%
Return On Equity TTM	33.4%

Stock Returns calculator for Gilead Sciences Stock including INR - Dollar returns

The Gilead Sciences stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Gilead Sciences investment value today

Current value as on today

₹1,63,176

Returns

₹63,176

(+63.18%)

Returns from Gilead Sciences Stock

₹58,966 (+58.97%)

Dollar Returns*

₹4,210 (+4.21%)

Indian investors sentiment towards Gilead Sciences Stock

-2.86%

Period: Jul 17, 2025 to Aug 16, 2025. Change in 30 Days versus previous period

Investment in Gilead Sciences Shares from India has dropped by -2.86% over the past 30 days, indicating reduced transactional activity.

Period: Jul 17, 2025 to Aug 16, 2025. Change in 30 Days versus previous period

Search interest for Gilead Sciences Stock from India on INDmoney has increased by 2% in the last 30 days, reflecting an upward trend in search activity.

Indian Mutual Funds that invest in Gilead Sciences Stock

Name	Shares Held	Change in Shares	% of Assets
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth	1964	0.00	1.17%
Motilal Oswal S&P 500 Index Fund Direct Growth	10055	-109.50	0.26%
ICICI Prudential NASDAQ 100 Index Fund Direct Growth	17707	-1078.36	0.79%

Global Institutional Holdings in Gilead Sciences Inc.

Name
Holdings %
Name
Holdings %
Vanguard Group Inc
9.47%
BlackRock Inc
9.36%
State Street Corp
4.80%
FMR Inc
4.72%
Capital Research Global Investors
4.40%
Capital World Investors
4.32%

Analyst Recommendation on Gilead Sciences Stock

Rating

Trend

Hold

47%Buy

52%Hold

0%Sell

Based on 38 Wall street analysts offering stock ratings for Gilead Sciences(by analysts ranked 0 to 5 stars)

Gilead Sciences Share Price Target

What analysts predicted

Upside of 3.67%

Target:

$122.69

Current:

$118.35

Gilead Sciences share price target is $122.69, a slight Upside of 3.67% compared to current price of $118.35 as per analysts' prediction.

Gilead Sciences Stock Insights

Price Movement
In the last 1 month, GILD stock has moved up by 8.8%
Increasing Revenue
Gilead Sciences Inc. has shown a positive trend in its revenue over the last two quarters. Revenue increased from $6.66 billion to $7.08 billion, reflecting an average growth of 5.9% per quarter.
Increasing Net Profit
Gilead Sciences Inc. has reported an increase in net profit for the last two quarters. The net profit rose from $1.31 billion to $1.96 billion, reflecting an average increase of 32.9% per quarter.

Gilead Sciences Inc. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$22.4B	↑ 1.46%
Net Income	$5.4B	↓ 1.26%
Net Profit Margin	23.99%	↓ 0.66%

	FY20	Y/Y Change
Revenue	$24.7B	↑ 9.98%
Net Income	$123.0M	↓ 97.72%
Net Profit Margin	0.5%	↓ 23.49%

	FY21	Y/Y Change
Revenue	$27.3B	↑ 10.6%
Net Income	$6.2B	↑ 4960.98%
Net Profit Margin	22.8%	↑ 22.3%

	FY22	Y/Y Change
Revenue	$27.3B	↓ 0.09%
Net Income	$4.6B	↓ 26.23%
Net Profit Margin	16.83%	↓ 5.97%

	FY23	Y/Y Change
Revenue	$27.1B	↓ 0.6%
Net Income	$5.7B	↑ 23.37%
Net Profit Margin	20.89%	↑ 4.06%

	FY24	Y/Y Change
Revenue	$28.8B	↑ 6.04%
Net Income	$480.0M	↓ 91.53%
Net Profit Margin	1.67%	↓ 19.22%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$6.7B	↓ 6.02%
Net Income	$-4.2B	↓ 391.81%
Net Profit Margin	-62.37%	↓ 82.46%

	Q2 FY24	Q/Q Change
Revenue	$7.0B	↑ 3.99%
Net Income	$1.6B	↓ 138.71%
Net Profit Margin	23.21%	↑ 85.58%

	Q3 FY24	Q/Q Change
Revenue	$7.5B	↑ 8.51%
Net Income	$1.3B	↓ 22.37%
Net Profit Margin	16.61%	↓ 6.6%

	Q4 FY24	Q/Q Change
Revenue	$7.6B	↑ 0.32%
Net Income	$1.8B	↑ 42.3%
Net Profit Margin	23.56%	↑ 6.95%

	Q1 FY25	Q/Q Change
Revenue	$6.7B	↓ 11.92%
Net Income	$1.3B	↓ 26.25%
Net Profit Margin	19.72%	↓ 3.84%

	Q2 FY25	Q/Q Change
Revenue	$7.1B	↑ 6.21%
Net Income	$2.0B	↑ 49.05%
Net Profit Margin	27.68%	↑ 7.96%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$17.8B	↑ 2.89%

	FY20	Y/Y Change
Profit	$20.1B	↑ 13.18%

	FY21	Y/Y Change
Profit	$20.7B	↑ 2.92%

	FY22	Y/Y Change
Profit	$21.6B	↑ 4.44%

	FY23	Y/Y Change
Profit	$27.1B	↑ 25.4%

	FY24	Y/Y Change
Profit	$22.5B	↓ 17.01%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$5.1B	↑ 2.19%

	Q2 FY24	Q/Q Change
Profit	$5.4B	↑ 5.36%

	Q3 FY24	Q/Q Change
Profit	$6.0B	↑ 10.39%

	Q4 FY24	Q/Q Change
Profit	$6.0B	↑ 0.28%

	Q1 FY25	Q/Q Change
Profit	$5.1B	↓ 14.38%

	Q2 FY25	Q/Q Change
Profit	$5.6B	↑ 8.84%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$9.1B	↑ 8.86%
Investing Cash Flow	$-7.8B	↓ 154.45%
Financing Cash Flow	$-7.6B	↓ 38.03%

	FY20	Y/Y Change
Operating Cash Flow	$8.2B	↓ 10.67%
Investing Cash Flow	$-14.6B	↑ 86.96%
Financing Cash Flow	$770.0M	↓ 110.09%

	FY21	Y/Y Change
Operating Cash Flow	$11.4B	↑ 39.37%
Investing Cash Flow	$-3.1B	↓ 78.58%
Financing Cash Flow	$-8.9B	↓ 1252.86%

	FY22	Y/Y Change
Operating Cash Flow	$9.1B	↓ 20.31%
Investing Cash Flow	$-2.5B	↓ 21.24%
Financing Cash Flow	$-6.5B	↓ 27.13%

	FY23	Y/Y Change
Operating Cash Flow	$8.0B	↓ 11.75%
Investing Cash Flow	$-2.3B	↓ 8.15%
Financing Cash Flow	$-5.1B	↓ 20.78%

	FY24	Y/Y Change
Operating Cash Flow	$10.8B	↑ 35.25%
Investing Cash Flow	$-3.4B	↑ 52.27%
Financing Cash Flow	$-3.4B	↓ 33.01%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$2.2B	↑ 2.31%
Investing Cash Flow	$-2.2B	↑ 203.58%
Financing Cash Flow	$-1.4B	↑ 23.84%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$1.3B	↓ 40.29%
Investing Cash Flow	$-307.0M	↓ 86.09%
Financing Cash Flow	$-3.0B	↑ 116.97%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$4.3B	↑ 225.21%
Investing Cash Flow	$-710.0M	↑ 131.27%
Financing Cash Flow	$-1.4B	↓ 53.3%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$3.0B	↓ 30.96%
Investing Cash Flow	$-225.0M	↓ 68.31%
Financing Cash Flow	$2.3B	↓ 263.89%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$1.8B	↓ 40.94%
Investing Cash Flow	$-415.0M	↑ 84.44%
Financing Cash Flow	$-3.4B	↓ 251.59%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$827.0M	↓ 52.93%
Investing Cash Flow	$-2.1B	↑ 409.88%
Financing Cash Flow	$-1.6B	↓ 54.26%

Gilead Sciences Technicals Summary

Sell

Neutral

Buy

Gilead Sciences is currently in a neutral trading position according to technical analysis indicators.

Gilead Sciences Inc. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Gilead Sciences Inc.	9.35%	12.44%	58.95%	81.56%	71.36%
Eli Lilly And Company	-9.12%	-18.19%	-23.92%	121.43%	358.04%
Johnson & Johnson	7.93%	13.99%	10.68%	5.94%	17.72%
Merck & Co. Inc.	5.34%	1.13%	-26.39%	-7.84%	-0.39%
Novo Nordisk A/s	-18.45%	-36.3%	-61.22%	2.07%	57.8%
Abbvie Inc	9.16%	5.27%	4.94%	46.22%	115.99%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Gilead Sciences Inc.	23.66	23.66	0.24	8.08	0.33	0.13	0.03	15.84
Eli Lilly And Company	44.68	44.68	0.96	22.82	0.86	0.17	0.01	20.38
Johnson & Johnson	18.69	18.69	1.06	10.85	0.3	0.08	0.03	32.6
Merck & Co. Inc.	12.75	12.75	0.81	8.93	0.35	0.13	0.04	19.57
Novo Nordisk A/s	13.0	13.0	1.47	24.84	0.79	0.22	0.03	37.82
Abbvie Inc	95.94	95.94	0.43	11.97	1.13	0.09	0.03	-0.1

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Gilead Sciences Inc.	Hold	$147.7B	71.36%	23.66	21.87%
Eli Lilly And Company	Buy	$613.6B	358.04%	44.68	25.91%
Johnson & Johnson	Buy	$420.1B	17.72%	18.69	25.0%
Merck & Co. Inc.	Buy	$206.7B	-0.39%	12.75	25.79%
Novo Nordisk A/s	Buy	$226.6B	57.8%	13.0	35.61%
Abbvie Inc	Buy	$355.9B	115.99%	95.94	6.45%

Gilead Sciences Dividend announcements

Gilead Sciences Dividends September, 2025
In the quarter ending September,2025. Gilead Sciences has declared dividend of $0.79

About Gilead Sciences Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Organization	Gilead Sciences
Employees	17600
CEO	Mr. Daniel P. O'Day
Industry	Health Technology

Key Management of Gilead Sciences Inc.

Name	Title
Mr. Daniel P. O'Day	Chairman & CEO
Mr. Andrew D. Dickinson	Chief Financial Officer
Ms. Deborah H. Telman J.D.	Executive VP of Corporate Affairs, General Counsel & Corporate Secretary
Ms. Johanna Mercier	Chief Commercial Officer
Ms. Diane E. Wilfong	Interim Corporate Controller, Chief Accounting Officer & Principal Accounting Officer
Ms. Jacquie Ross C.F.A.	Senior Vice President of Treasury and Investor Relations
Ms. Jyoti K. Mehra	Executive Vice President of Human Resources
Dr. Linda Slanec Higgins Ph.D.	Senior Vice President of Research, Innovation & Portfolio
Dr. Flavius Martin M.D.	Executive Vice President of Research
Ms. Janet Dorling	Senior Vice President of Intercontinental Region & Global Patient Solutions

Important FAQs about investing in GILD Stock from India :

What is Gilead Sciences share price today?

Gilead Sciences share price today is $118.35 as on August 16, 2025 at 1:29 AM IST at the close of the market. Gilead Sciences share today touched a day high of $118.98 and a low of $117.75.

What is the 52 week high and 52 week low for Gilead Sciences share?

Gilead Sciences share touched a 52 week high of $121.83 and a 52 week low of $72.89. Gilead Sciences stock price today, August 16, 2025 at 1:29 AM IST is trending at $118.35, lower by 2.86% versus the 52 week high.

How to invest in Gilead Sciences Stock (GILD) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Gilead Sciences on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Gilead Sciences Shares that will get you 0.0127 shares as per Gilead Sciences share price of $118.35 per share as on August 16, 2025 at 1:29 AM IST.

What is the minimum amount required to buy Gilead Sciences Stock (GILD) from India?

Indian investors can start investing in Gilead Sciences (GILD) shares with as little as ₹87.492 or $1 (as of August 17, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹874.92 in Gilead Sciences stock (as per the Rupee-Dollar exchange rate as on August 17, 2025). Based on Gilead Sciences share’s latest price of $118.35 as on August 16, 2025 at 1:29 AM IST, you will get 0.0845 shares of Gilead Sciences. Learn more about fractional shares .

What are the returns that Gilead Sciences has given to Indian investors in the last 5 years?

Gilead Sciences stock has given 71.36% share price returns and 17.06% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?